Gilead signs antibiotic development deal with CURx Pharmaceuticals

02/20/2014 | Genetic Engineering & Biotechnology News

Gilead Sciences and CURx Pharmaceuticals agreed to collaborate in the development of a broad spectrum combination antibiotic for the treatment of Pseudomonas aeruginosa lung infection, which affects cystic fibrosis patients. The drug, a combination of antibiotics fosfomycin and tobramycin, is ready to enter late-stage trials after yielding positive results in a midstage study involving CF patients with Pseudomonas aeruginosa infection.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN